TD Cowen raised the firm’s price target on Guardant Health (GH) to $72 from $63 and keeps a Buy rating on the shares. The firm said the company has momentum across all its businesses with ample white space ahead. While the oncology Dx sector has done well, Gurardant stands out for its screening position/opportunity and its epigenetics approach.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $80 from $70 at BTIG
- Guardant Health price target raised to $67 from $56 at Guggenheim
- Guardant Health price target raised to $70 from $65 at Mizuho
- Guardant Health’s Strong Growth Trajectory and Unique Oncology Approach Earns Buy Rating
- Wolfe upgrades Guardant to Outperform after ‘solid’ analyst day